Literature DB >> 16244833

[PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis].

S Kim1, E Genth, T Krieg, N Hunzelmann.   

Abstract

We describe a 72- year-old patient with a ten year history of anti-PM-Scl positive systemic sclerosis associated with inclusion-body myositis. While the association of dermatomyositis and polymyositis with anti-PM-Scl positive systemic sclerosis is frequently reported, inclusion-body myositis was, to the best of our knowledge, only previously described once in association with anti-PM-Scl-positive systemic sclerosis. The distinction between inclusion-body myositis and other forms of inflammatory myopathy, like the histopathologically well distinguishable polymyositis or dermatomyositis, is relevant because of the poor response of inclusion- body myositis to immunosuppressive treatment. Our case underlines that in patients with anti-PM-Scl-positive systemic sclerosis and treatment resistant progressive myopathy the diagnosis of inclusion body myositis should be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244833     DOI: 10.1007/s00393-005-0664-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  26 in total

Review 1.  What is the relation between crystals and osteoarthritis?

Authors:  A L Concoff; K C Kalunian
Journal:  Curr Opin Rheumatol       Date:  1999-09       Impact factor: 5.006

2.  Inclusion Body Myositis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

3.  Inclusion body myositis: atypical clinical presentations.

Authors:  I Schlesinger; D Soffer; A Lossos; Z Meiner; Z Argov
Journal:  Eur Neurol       Date:  1996       Impact factor: 1.710

Review 4.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

5.  Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments.

Authors:  J R Mendell; Z Sahenk; T Gales; L Paul
Journal:  Arch Neurol       Date:  1991-12

6.  Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.

Authors:  N Mowzoon; A Sussman; W G Bradley
Journal:  J Neurol Sci       Date:  2001-04-01       Impact factor: 3.181

7.  Inclusion body myositis presenting as treatment-resistant polymyositis.

Authors:  L H Calabrese; H Mitsumoto; S M Chou
Journal:  Arthritis Rheum       Date:  1987-04

8.  Inclusion body myositis. Observations in 40 patients.

Authors:  B P Lotz; A G Engel; H Nishino; J C Stevens; W J Litchy
Journal:  Brain       Date:  1989-06       Impact factor: 13.501

9.  Inclusion body myositis: explanation for poor response to immunosuppressive therapy.

Authors:  R J Barohn; A A Amato; Z Sahenk; J T Kissel; J R Mendell
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

10.  Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes.

Authors:  G Reimer; U Scheer; J M Peters; E M Tan
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

View more
  1 in total

Review 1.  [Dermatomyositis-specific antibodies].

Authors:  L Bodoki; M Nagy-Vincze; Z Griger; K Dankó
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.